Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Stapokibart Was Granted Marketing Approval From National Medical Products Administration For The Treatment Of Moderate-to-severe Atopic Dermatitis in Adults 2024-09-13 00:07
Keymed Biosciences Announces Long-term Efficacy and Safety Data from a Phase III Clinical Trial of Stapokibart for the Treatment of Moderate-to-severe Atopic Dermatitis 2024-06-03 09:14
Keymed Biosciences Announces 2023 Annual Results and Business Updates 2024-03-27 01:16
Keymed Biosciences | The Latest Results from the Phase Ia Clinical Study of CMG901 was presented at the 2023 ASCO GI CANCERS SYMPOSIUM 2023-01-18 09:52
China CDE Grants CMG901 Breakthrough Therapy Designation for Claudin 18.2-Positive Advanced Gastric & Gastroesophageal Junction Cancer 2022-09-22 13:05
Keymed Biosciences Announces Dosing of First Patient in Phase I Trial of Bispecific Antibody CM350 2022-06-10 18:42
FDA granted CMG901 Fast Track Designation for unresectable or metastatic gastric and gastroesophageal junction cancer which have relapsed and/or are refractory to approved therapies 2022-04-20 10:27
CMG901 for the treatment of gastric cancer and gastroesophageal junction adenocarcinoma was granted the Orphan-drug Designation by the Food and Drug Administration of the United States 2022-04-12 15:45
Keymed has been included as eligible stocks of the Shenzhen-Hong Kong Stock Connect 2022-03-07 15:57
1